Last reviewed · How we verify
Rotigotine, extended-release microspheres
At a glance
| Generic name | Rotigotine, extended-release microspheres |
|---|---|
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD (PHASE1)
- A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD (PHASE3)
- A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro (PHASE1)
- A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003 (PHASE1)
- A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers (PHASE1)
- A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease (PHASE1)
- A Study of LY03003 in Patients With Early-stage Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |